期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 67, 期 2, 页码 469-480出版社
IOS PRESS
DOI: 10.3233/JAD-181035
关键词
Alzheimer's disease; Ang(1-7)/Mas receptor system; angiotensin II/AT(1) receptor system; angiotensin IV/AT(4) receptor system; insulin-regulated aminopeptidase (IRAP); renin-angiotensin system (RAS)
资金
- Michael J Fox Foundation
- Alzheimer's Drug Discovery Foundation
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive neuron losses in memoryassociated brain structures that rob patients of their dignity and quality of life. Five drugs have been approved by the FDA to treat AD but none modify or significantly slow disease progression. New therapies are needed to delay the course of this disease with the ultimate goal of preventing neuron losses and preserving memory functioning. In this review we describe the renin-angiotensin II (AngII) system (RAS) with specific regard to its deleterious contributions to hypertension, facilitation of neuroinflammation and oxidative stress, reduced cerebral blood flow, tissue remodeling, and disruption of memory consolidation and retrieval. There is evidence that components of the RAS, AngIV and Ang(1-7), are positioned to counter such damaging influences and these systems are detailed with the goal of drawing attention to their importance as drug development targets. Ang(1-7) binds at the Mas receptor, while AngIV binds at the AT4 receptor subtype, and these receptor numbers are significantly decreased in AD patients, accompanied by declines in brain aminopeptidases A and N, enzymes essential for the synthesis of AngIV. Potent analogs may be useful to counter these changes and facilitate neuronal functioning and reduce apoptosis in memory associated brain structures of AD patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据